These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34021923)

  • 1. Dopaminergic and Serotonergic Degeneration and Cortical [
    Orso B; Arnaldi D; Girtler N; Brugnolo A; Doglione E; Mattioli P; Biassoni E; Fancellu R; Massa F; Bauckneht M; Chiola S; Morbelli S; Nobili F; Pardini M
    Mov Disord; 2021 Oct; 36(10):2293-2302. PubMed ID: 34021923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a
    Pilotto A; Schiano di Cola F; Premi E; Grasso R; Turrone R; Gipponi S; Scalvini A; Cottini E; Paghera B; Garibotto V; Rizzetti MC; Bonanni L; Borroni B; Morbelli S; Nobili F; Guerra UP; Perani D; Padovani A
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1642-1651. PubMed ID: 31098748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray matter correlates of dopaminergic degeneration in Parkinson's disease: A hybrid PET/MR study using (18) F-FP-CIT.
    Choi H; Cheon GJ; Kim HJ; Choi SH; Kim YI; Kang KW; Chung JK; Kim EE; Lee DS
    Hum Brain Mapp; 2016 May; 37(5):1710-21. PubMed ID: 26846350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.
    Eshuis SA; Jager PL; Maguire RP; Jonkman S; Dierckx RA; Leenders KL
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):454-62. PubMed ID: 19037637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of
    Lee I; Kim JS; Park JY; Byun BH; Park SY; Choi JH; Moon H; Kim JY; Lee KC; Chi DY; Kim KM; Lim I; Kang JH; Ahn SH; Kim BI; Ha JH; Lim SM
    Synapse; 2018 Jul; 72(7):e22032. PubMed ID: 29486515
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
    Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nigrostriatal Degeneration in the Cognitive Part of the Striatum in Parkinson Disease Is Associated With Frontomedial Hypometabolism.
    Apostolova I; Lange C; Frings L; Klutmann S; Meyer PT; Buchert R
    Clin Nucl Med; 2020 Feb; 45(2):95-99. PubMed ID: 31876812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease.
    Orso B; Arnaldi D; Famà F; Girtler N; Brugnolo A; Doglione E; Filippi L; Massa F; Peira E; Bauckneht M; Morbelli S; Nobili F; Pardini M
    Cortex; 2020 Sep; 130():401-412. PubMed ID: 32755727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
    Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
    Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease.
    Lee CS; Kim SJ; Oh SJ; Kim HO; Yun SC; Doudet D; Kim JS
    Ann Nucl Med; 2014 Nov; 28(9):874-9. PubMed ID: 25008292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of dopamine transporters in Parkinson disease: a meta-analysis of
    Kong Y; Zhang C; Liu K; Wagle Shukla A; Sun B; Guan Y
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1524-1534. PubMed ID: 32794655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
    Song IU; Chung YA; Oh JK; Chung SW
    Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Muñoz-Delgado L; Labrador-Espinosa MÁ; Macías-García D; Jesús S; Benítez Zamora B; Fernández-Rodríguez P; Adarmes-Gómez AD; Reina Castillo MI; Castro-Labrador S; Silva-Rodríguez J; Carrillo F; García Solís D; Grothe MJ; Mir P
    Mov Disord; 2023 May; 38(5):755-763. PubMed ID: 36912400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between dopamine transporter density measured by
    Maekawa T; Sato N; Ota M; Sugiyama A; Sone D; Enokizono M; Kimura Y; Mukai Y; Murata M; Takano H; Imabayashi E; Matsuda H; Kunimatsu A; Abe O
    Jpn J Radiol; 2017 Dec; 35(12):755-759. PubMed ID: 29063467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson's Disease.
    Orso B; Arnaldi D; Peira E; Famá F; Giorgetti L; Girtler N; Brugnolo A; Mattioli P; Biassoni E; Donniaquio A; Massa F; Bauckneht M; Miceli A; Morbelli S; Nobili F; Pardini M
    J Parkinsons Dis; 2022; 12(6):1945-1955. PubMed ID: 35811536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.